Disparities in access to neuro-oncologic care in the United States
- PMID: 20231625
- DOI: 10.1001/archsurg.2009.288
Disparities in access to neuro-oncologic care in the United States
Abstract
Hypothesis: Race/ethnicity and social status influence admission to high-volume hospitals among patients who undergo craniotomy for tumor biopsy or resection.
Design: Retrospective analysis of the Nationwide Inpatient Sample (1988-2005), with additional factors from the Area Resource File.
Setting: A 20% representative sample of all hospitals in 37 US states.
Patients: A total of 76 436 patients 18 years or older who were admitted and underwent craniotomy for tumor biopsy or resection.
Main outcome measures: Odds ratios (ORs) for the association of age, sex, race/ethnicity, insurance status, Charlson Comorbidity Index, and county-level characteristics with admission to high-volume hospitals (>50 craniotomies per year) or low-volume hospitals.
Results: A total of 25 481 patients (33.3%) were admitted to high-volume hospitals. Overall access to high-volume hospitals improved over time. However, racial/ethnic disparities in access to high-volume hospitals dramatically worsened for Hispanics (OR, 0.49) and African Americans (OR, 0.62) in recent years. Factors associated with better access to high-volume hospitals included years since 1988 (OR, 1.11), greater countywide neurosurgeon density (OR, 1.66), and higher countywide median household income (OR, 1.71). Factors associated with worse access to high-volume hospitals included older age (OR, 0.34 per year increase), increased countywide poverty rate (OR, 0.57), Hispanic race/ethnicity (OR, 0.68), and higher Charlson Comorbidity Index (OR, 0.96 per point increase).
Conclusions: African Americans and Hispanics have disproportionately worse access to high-quality neuro-oncologic care over time compared with whites. Higher countywide median household income and decreased countywide poverty rate were associated with better access to high-volume hospitals, implicating socioeconomic factors in predicting admission to high-quality centers.
Comment in
-
What do we gain and lose from database studies?Arch Surg. 2010 Mar;145(3):253-4. doi: 10.1001/archsurg.2009.293. Arch Surg. 2010. PMID: 20329346 No abstract available.
Similar articles
-
Disparities in access to pediatric neurooncological surgery in the United States.Pediatrics. 2009 Oct;124(4):e688-96. doi: 10.1542/peds.2009-0377. Epub 2009 Sep 28. Pediatrics. 2009. PMID: 19786429
-
Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988-2004.Neurosurgery. 2010 Mar;66(3):427-37; discussion 437-8. doi: 10.1227/01.NEU.0000365265.10141.8E. Neurosurgery. 2010. PMID: 20124933
-
Equal access to healthcare does not eliminate disparities in the management of adults with appendicitis.J Surg Res. 2011 Oct;170(2):209-13. doi: 10.1016/j.jss.2011.02.009. Epub 2011 Mar 23. J Surg Res. 2011. PMID: 21470638
-
Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.Ann Surg Oncol. 2022 May;29(5):3232-3250. doi: 10.1245/s10434-021-11258-6. Epub 2022 Jan 23. Ann Surg Oncol. 2022. PMID: 35067789
-
Disparities in Access to High-Volume Surgeons and Specialized Care.Endocrinol Metab Clin North Am. 2023 Dec;52(4):689-703. doi: 10.1016/j.ecl.2023.05.006. Epub 2023 Jun 4. Endocrinol Metab Clin North Am. 2023. PMID: 37865482 Review.
Cited by
-
Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI).J Neurooncol. 2022 Jul;158(3):349-357. doi: 10.1007/s11060-022-04020-9. Epub 2022 May 3. J Neurooncol. 2022. PMID: 35503190
-
Racial Differences in Disease Presentation and Management of Intracranial Meningioma.J Neurol Surg B Skull Base. 2019 Dec;80(6):555-561. doi: 10.1055/s-0038-1676788. Epub 2018 Dec 21. J Neurol Surg B Skull Base. 2019. PMID: 31750040 Free PMC article.
-
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.Neuro Oncol. 2020 Aug 17;22(8):1182-1189. doi: 10.1093/neuonc/noaa019. Neuro Oncol. 2020. PMID: 32002547 Free PMC article. Clinical Trial.
-
Social Determinants of Health and Limitation of Life-Sustaining Therapy in Neurocritical Care: A CHoRUS Pilot Project.Neurocrit Care. 2024 Dec;41(3):866-879. doi: 10.1007/s12028-024-02007-0. Epub 2024 Jun 6. Neurocrit Care. 2024. PMID: 38844599
-
A participatory evaluation framework in the establishment and implementation of transdisciplinary collaborative centers for health disparities research.Eval Program Plann. 2017 Feb;60:37-45. doi: 10.1016/j.evalprogplan.2016.08.020. Epub 2016 Sep 13. Eval Program Plann. 2017. PMID: 27669394 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical